Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjectswith Type 2 Diabetes ORVILLE G. KOLTERMAN, JOHN B. BUSE, MARK S. FINEMAN, ELING GAINES, SONJA HEINTZ, THOMAS A. BICSAK, KRISTIN TAYLOR, DENNIS KIM, MARIA AISPORNA, YAN WANG, AND ALAIN D. BARON Amylin Pharmaceuticals, Inc. (O.G.K., M.S.F., E.G., S.H., T.A.B., K.T., D.K., M.A., Y.W., A.D.B.), San Diego, California 92121; and University of North Carolina School of Medicine (J.B.B.), Chapel Hill, North Carolina 27599 Despite the advent of new treatments, glucose control in the type 2 diabetes population is unsatisfactory. AC2993 (syn-thetic exendin-4; exenatide), a novel glucose-dependent insu-linotropic agent, exhibited notable antidiabetic potential intwo clinical studies in patients with type 2 diabetes. In studyA, 24 subjects received sc injections of study medication (0.1 /H9262g/kg AC2993 or placebo) twice daily with meals for 5 d. Sta-